argenx SE
XBRU:ARGX

Watchlist Manager
argenx SE Logo
argenx SE
XBRU:ARGX
Watchlist
Price: 598.2 EUR -1.06%
Market Cap: 35.8B EUR
Have any thoughts about
argenx SE?
Write Note

argenx SE
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

argenx SE
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
argenx SE
XBRU:ARGX
Additional Paid In Capital
$5.7B
CAGR 3-Years
19%
CAGR 5-Years
47%
CAGR 10-Years
62%
Pharming Group NV
AEX:PHARM
Additional Paid In Capital
$487.1m
CAGR 3-Years
8%
CAGR 5-Years
4%
CAGR 10-Years
6%
ProQR Therapeutics NV
NASDAQ:PRQR
Additional Paid In Capital
€416.4m
CAGR 3-Years
1%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
Additional Paid In Capital
$1.2B
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
16%
Merus NV
NASDAQ:MRUS
Additional Paid In Capital
$1.6B
CAGR 3-Years
36%
CAGR 5-Years
42%
CAGR 10-Years
N/A
LAVA Therapeutics NV
NASDAQ:LVTX
Additional Paid In Capital
$194.4m
CAGR 3-Years
68%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

argenx SE
Glance View

Market Cap
35.8B EUR
Industry
Biotechnology

In a landscape where biotechnology companies tirelessly strive to transform scientific insight into therapeutic breakthroughs, argenx SE stands out with its innovative approach to harnessing the body's own immune system to address severe autoimmune diseases. Originating from the biopharmaceutical hubs of Belgium and the Netherlands, argenx was founded in 2008 and has since positioned itself at the forefront of immunology. At the heart of argenx's operations lies its proprietary SIMPLE Antibody™ technology platform, which engineers differentiated therapeutic antibodies. Guided by a deep understanding of disease biology, the company partners closely with academic institutions and leading pharmaceutical companies to transform promising research insights into viable drug candidates. The company's financial sustenance is woven into its intricate business model, which revolves around the development and commercialization of therapeutic antibodies. Their flagship product, efgartigimod, has made significant strides in treating autoimmune diseases such as generalized myasthenia gravis, showcasing the company's ability to translate its scientific endeavors into substantial revenue streams. Argenx generates income primarily through product sales, milestone payments, and royalties from collaborative partnerships. As the company continues to advance its pipeline and expand its global presence, it demonstrates a robust commitment to addressing unmet medical needs while maintaining a keen eye on sustainable growth and profitability. This delicate balance of innovation and financial acumen allows argenx to reinforce its position in the competitive biotech industry.

ARGX Intrinsic Value
643.62 EUR
Undervaluation 7%
Intrinsic Value
Price

See Also

What is argenx SE's Additional Paid In Capital?
Additional Paid In Capital
5.7B USD

Based on the financial report for Jun 30, 2024, argenx SE's Additional Paid In Capital amounts to 5.7B USD.

What is argenx SE's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
62%

Over the last year, the Additional Paid In Capital growth was 31%. The average annual Additional Paid In Capital growth rates for argenx SE have been 19% over the past three years , 47% over the past five years , and 62% over the past ten years .

Back to Top